Xenon Pharmaceuticals (XENE) Fundamental Analysis: Revenue, Earnings & Valuation

4.24 / 10

Netural

XENE's fundamental profile is mixed: strong revenue and profit momentum are offset by a low current-asset turnover and elevated asset-to-market value. Key positives include a 100% gross profit margin and 100.2% net-profit-to-total-profit ratio, yet the -0.5007 Asset-MV reading and poor historical returns for Current assets turnover (-1.88%) temper enthusiasm. Overall, fundamentals lean neutral with pockets of strength and weakness.

Analysis Checks(8/10)

Revenue-MV

Value-0.26

Score2/3

Weight21.25%

1M Return11.69%

Inventory turnover ratio

Value47.85

Score3/3

Weight8.18%

1M Return5.26%

Gross profit margin (%)

Value100.00

Score3/3

Weight18.72%

1M Return10.80%

Profit-MV

Value0.46

Score2/3

Weight13.94%

1M Return7.79%

PB-ROE

Value4.01

Score2/3

Weight19.58%

1M Return10.68%

Current assets turnover ratio

Value0.01

Score0/3

Weight-2.55%

1M Return-1.88%

Fixed assets turnover ratio

Value0.78

Score2/3

Weight0.18%

1M Return0.12%

Asset-MV

Value-0.50

Score0/3

Weight4.76%

1M Return2.94%

Cash-MV

Value-0.07

Score2/3

Weight13.96%

1M Return7.73%

Net profit / Total profit (%)

Value100.20

Score2/3

Weight1.97%

1M Return1.28%

Is XENE fundamentally strong?

XENE scores 4.24/10 on fundamentals and holds a Fair valuation at present. Backed by its -36.62% ROE, 0.00% net margin, -11.49 P/E ratio, 5.72 P/B ratio, and -38.43% earnings growth, these metrics solidify its Netural investment rating.